Bg. Angeja et al., Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women, J AM COL C, 38(5), 2001, pp. 1297-1301
Citations number
22
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objectives We examined the association of hormone therapy (HRT) with hemorr
hagic and ischemic stroke among postmenopausal women with acute myocardial
infarction (AMI).
Background Hemorrhagic and ischemic strokes are common complications of AML
and women are at increased risk for hemorrhagic stroke after thrombolytic
therapy. This risk may be related to female hormones.
Methods Using data from the National Registry of Myocardial Infarction-3, w
e studied 114,724 women age 55 years or older admitted to the hospital for
AMI, of whom 7,353 reported HRT use on admission. We determined rates of in
-hospital hemorrhagic and ischemic stroke stratified by HRT use and estimat
ed the independent association of HRT with each stroke type using multivari
able logistic regression.
Results The HRT users were younger than non-users, had fewer risk factors f
or stroke including diabetes and prior stroke, and received more pharmacolo
gic and invasive therapy including cardiac catheterization. A total of 2,15
2 (1.9%) in-hospital strokes occurred, with 442 (0.4%) hemorrhagic, 1,017 (
0.9%) ischemic and 693 (0.6%) unspecified. Among HRT users and non-users, t
he rates of hemorrhagic stroke (0.40% vs. 0.42%, p=1.00) and ischemic strok
e (0.80% vs. 0.96%, p=0.11) were similar. Among 13,328 women who received t
hrombolytic therapy, the rate of hemorrhagic stroke was not significantly d
ifferent for users and non-users (1.6% vs. 2.1%, p=0.22). After adjustment
for baseline, and treatment differences, HRT was not associated with hemorr
hagic (odds ratio [OR], 0.88; 95% confidence intervals [CI], 0.58 to 1.35)
or ischemic stroke (OR, 0.89; CI, 0.66 to 1.18).
Conclusions Acute myocardial infarction is a high-risk setting for stroke a
mong postmenopausal women, but HRT does not appear to modify that risk. Cli
nicians should not alter their approach; to thrombolytic therapy based on H
RT use. (J Am Coll Cardiol 2001;38:1297-301) (C) 2001 by the American Colle
ge of Cardiology.